Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | PTEN del STK11 del |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
PTEN del STK11 del | endometrial carcinoma | sensitive | Buparlisib + Olaparib | Preclinical | Actionable | In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) significantly induced apoptosis and reduced tumor volume by 1.83 fold in a STK11 and PTEN double knock-out mouse model of endometrial carcinoma (PMID: 28945226). | 28945226 | |
PTEN del STK11 del | endometrial carcinoma | no benefit | Olaparib | Preclinical | Actionable | In a preclinical study, Lynparza (olaparib) monotherapy demonstrated limited anti-tumor effect in a STK11 and PTEN double knock-out mouse model of endometrial carcinoma (PMID: 28945226). | 28945226 | |
PTEN del STK11 del | endometrial carcinoma | predicted - sensitive | Buparlisib | Preclinical | Actionable | In a preclinical study, Buparlisib (BKM120) monotherapy resulted in stable disease in a STK11 and PTEN double knock-out mouse model of endometrial carcinoma (PMID: 28945226). | 28945226 |